DDInter1335 DDInter131
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Omacetaxine mepesuccinate {u} (Compound) binds {v} (Gene) RPL3
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) DUSP8
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) B4GAT1
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rituximab
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Indomethacin
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Omacetaxine mepesuccinate (Compound) binds RPL3 (Gene)
Omacetaxine mepesuccinate (Compound) upregulates DUSP8 (Gene)
Omacetaxine mepesuccinate (Compound) downregulates B4GAT1 (Gene)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Rituximab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Indomethacin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Avapritinib